Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 06, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps" SAN FRANCISCO, March 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”).
Read More
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.
Read More
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action
Published: March 04, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 03, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CORCEPT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTEN.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: March 03, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps" SAN FRANCISCO, March 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Published: March 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026.
Read More
Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Published: March 02, 2026 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CORCEPT THERAPEUTICS INCORPORATED (CORT), CONTACT THE LAW OFFICES OF HOWAR.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept " or "the Company") (NASDAQ: CORT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CORT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 21, 2026.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
Published: February 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Incorporated, (“Corcept” or the "Company") (NASDAQ: CORT) investors of a class action on behalf of investors that bought securities between October 31, 2024 and December 31, 2025, inclusive (the “Class Period”). Corcept investors have until April 21, 2026 to file a lead plaintiff motion.
Read More
ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action - CORT
Published: February 26, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action
Published: February 26, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). Corcept investors have until April 21, 2026 to file a lead plaintiff motion. IF YO.
Read More
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
CORT Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: February 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Corcept's Q4 Earnings and Revenues Fall Short of Estimates
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Negative
CORT misses Q4 earnings and revenue estimates despite 11% sales growth year over year.
Read More
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Published: February 24, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $CORT #CORT--The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant's NDA.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
Read More
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Corcept class action lawsuit seeks to represent purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"). Captioned Allegheny County Employees' Retirement System v.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Therapeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Therapeutics Incorporated?
Read More
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Published: February 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Therapeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Therapeutics Incorporated?
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500